Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuroimage Clin
Autors principals: Ottoy, Julie, Niemantsverdriet, Ellis, Verhaeghe, Jeroen, De Roeck, Ellen, Struyfs, Hanne, Somers, Charisse, wyffels, Leonie, Ceyssens, Sarah, Van Mossevelde, Sara, Van den Bossche, Tobi, Van Broeckhoven, Christine, Ribbens, Annemie, Bjerke, Maria, Stroobants, Sigrid, Engelborghs, Sebastiaan, Staelens, Steven
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Regular Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://ncbi.nlm.nih.gov/pubmed/30927601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nicl.2019.101771
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars